The new India-UK trade agreement grants duty-free access for Indian pharmaceutical and medical device exports to the UK. This pact aims to grow India's current $1 billion export share by removing tariffs on 99% of product lines. While industry players welcome the growth potential, they are seeking strict rules of origin to prevent third-country imports from undermining domestic manufacturers.
The recently signed India-UK Comprehensive Economic and Trade Agreement (CETA) marks a significant step for Indian healthcare exporters, providing them with zero-duty access to the United Kingdom. This agreement is expected to simplify regulatory hurdles and lower costs, helping Indian firms compete more effectively in a UK pharmaceutical import market worth nearly $30 billion annually. Currently, India exports approximately $900 million in medicines and $130 million in medical devices to the UK each year, leaving substantial room for expansion under the new terms.
Impact on Generic Drug Makers
Under the provisions of CETA, roughly 99% of Indian product lines will benefit from zero-duty access, specifically covering 56 key pharmaceutical tariff lines. This move is particularly advantageous for Indian generic drug manufacturers, who are already recognized for their cost-efficiency. As many global patents on high-value medicines are set to expire, Indian companies are well-positioned to supply affordable alternatives to the UK market. Furthermore, as the UK seeks to diversify its supply chains away from a heavy reliance on Chinese manufacturing, Indian firms that maintain strong international quality standards may emerge as preferred partners.
Industry Concerns Over Safeguards
Despite the positive outlook for export volumes, the Association of Indian Medical Device Industry (AiMeD) has raised concerns regarding the potential for trade circumvention. Industry representatives have urged the Indian government to enforce strict rules of origin to ensure that the tariff benefits are not exploited by third-country manufacturers, such as those from China, routing goods through the UK to bypass local duties. There is also a push for regulatory reciprocity, with industry bodies suggesting that India implement factory inspections for UK-based exporters to ensure a level playing field and maintain product safety standards.
Broader Healthcare Collaboration
Beyond the exchange of physical goods, the CETA framework includes provisions for deeper collaboration in healthcare services. This includes partnerships between Indian and UK hospitals, joint ventures in digital health, and expanded cooperation in clinical research. The agreement also allows for greater educational exchange, potentially enabling healthcare institutions to expand their operational presence in each other’s markets.
Investors will now look toward the implementation phase of the agreement, specifically tracking how the government addresses the requests for customs safeguards. Additionally, market participants will monitor whether individual pharmaceutical and medical device companies can successfully leverage this zero-duty access to gain market share in the UK against established global competitors.